CytomX Therapeutics, Inc. Interest Receivable, Current
CytomX Therapeutics, Inc. (CTMX) had Interest Receivable, Current of $1.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:InterestReceivableCurrent · last filed 2026-08-06
- 2026-06-30: Interest Receivable, Current $1.50M.
- 2026-03-31: Interest Receivable, Current $1.50M.
- 2025-12-31: Interest Receivable, Current $500.00K.
- 2024-12-31: Interest Receivable, Current $22.00K.
| Period end | Interest Receivable, Current |
|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $500.00K 10-Q · filed 2026-08-06 |
| 2024-12-31 | $22.00K 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |